Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)

NCT07562152 is registered in ClinicalTrials.gov with Immuneering Corporation as lead sponsor.

NCT NCT07562152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07562152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)
Lead sponsor
Immuneering Corporation
Phase
Phase 3
Overall status
Recruiting
Start date
June 5, 2026
Completion date
February 28, 2029
Enrollment
510 (estimated)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma, pancreatic adenocarcinoma metastatic, pancreatic cancer, pancreatic cancer metastatic, pancreatic ductal adenocarcinoma, pancreatic ductal adenocarcinoma (pdac), pdac, pdac - pancreatic ductal adenocarcinoma